Analysis Medical Properties Trust Returns to Profitability in Q4, Resolves Majority of Prospect Restructuring 1 month ago Medical Properties Trust, Inc. (NYSE: MPT), one of the world’s largest owners of hospital real estate, reported a return to… Claros Mortgage Trust Reports Fourth Quarter GAAP Loss on Increased Credit Reserves 1 month ago The commercial mortgage real estate investment trust posted a $219.2 million net loss for the final quarter of 2025, driven… Earnings Preview: J.M. Smucker (SJM) projected to see higher sales in Q3 2026 1 month ago Shares of The J.M. Smucker Co. (NYSE: SJM) stayed green on Thursday. The stock has gained 4% over the past… KKR’s Fundraising Machine Accelerates 1 month ago Executive Summary KKR & Co. Inc. has evolved into one of the world’s largest alternative asset managers, benefiting from structural… Endava PLC Reports Q2 2026 Earnings Results 1 month ago About Endava PLC Endava PLC (NYSE: DAVA) is a UK-based global technology services company that specializes in digital transformation, agile… Materialise Reports Q4 Revenue Growth Amid Euronext Brussels Listing 1 month ago The 3D printing specialist recorded a 6.8% rise in quarterly revenue and initiated a 30 million euro share buyback program.… Air France-KLM Delivers Record 2025 Profit on Premium Growth and Fleet Modernization 1 month ago Air France‑KLM S.A. (Euronext: AF) Market Cap ~€3.1 billion — Europe’s integrated airline group combining Air France and KLM Royal Dutch… C3is Inc. Swings to Full-Year Profit as Fleet Expansion Drives 2025 Growth 1 month ago C3is Inc. (Nasdaq: CISS), a Greece-based ship-owning company, reported a sharp turnaround in its full-year 2025 financial results on Thursday,… Six Flags Reports Full-Year Revenue of $3.1 Billion Amid Infrastructure Investments 1 month ago Six Flags Entertainment Corporation (NYSE: SIX), the largest regional amusement park operator in North America posts fourth-quarter net revenues of… Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales 1 month ago Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported fourth-quarter 2025 results showing continued commercial uptake of its lead product Rezdiffra (resmetirom), with… Next» « Previous